Physician profile
Sara E White
NPI 1851773444
$3,295.09
in general payments reported to CMS, 2019-2025
24 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 93% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.18 · 2022: $533 · 2023: $789 · 2024: $495 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $612 · Consulting Fee: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.32 |
| Education | $611.78 |
| Consulting Fee | $562.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $799.68 | 2022-2025 | Andexxa, Lynparza, Enhertu |
| Abbvie INC. | $796.09 | 2023-2025 | |
| Astellas Pharma US INC | $497.82 | 2023-2024 | Veozah |
| Pfizer INC. | $173.28 | 2021-2025 | |
| Eisai INC. | $125.78 | 2024-2025 | |
| Seagen INC. | $117.59 | 2022-2025 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2023-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $102.28 | 2022-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $93.54 | 2024-2025 | |
| Kite Pharma, INC. | $79.06 | 2022-2023 | |
| Daiichi Sankyo INC. | $65.06 | 2024-2025 | Enhertu, Datroway |
| Genmab U.S., INC. | $62.46 | 2023-2025 | Tivdak |
| Genzyme Corporation | $47.54 | 2022-2025 | |
| Janssen Biotech, INC. | $38.86 | 2023-2025 | Rybrevant |
| Karyopharm Therapeutics INC. | $34.59 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.61 | 2022 | |
| Novo Nordisk INC | $21.58 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.05 | 2022 | |
| Mirati Therapeutics, INC. | $16.63 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2025 | Fruzaqla |
| Geron Corporation | $14.96 | 2024 | Rytelo |
| Aveo Pharmaceuticals, INC. | $13.80 | 2022 | |
| Morphosys, US INC. | $13.48 | 2022 | |
| Lilly USA, LLC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.